Loading market quotes…

Subscribe free
IPO Field Notes5 minFreeGBC Research

Amaero, vVARDIS, Windward Bio: IPO research

A powder maker, two dentists and a twice-a-year asthma shot

IPO Field Notes, grey cover with a listing bell

Most new public investors have experienced finding out about an IPO through a rapid spike in a stock’s value or through an “explosion” of headlines. After learning about these companies, most new public investors want to know everything possible about the business.

In order to help you with this information while there is such limited coverage available, at IPO Field Notes, we provide this information for you. We will also review and cover these companies every approximately two weeks (or sooner if necessary) to identify who possess unique business models, technological advancements worth investigating, or products that people outside of Wall Street recognize and understand.

Like all Operators/CEOs evaluating potential investments, we examine how each company generates revenue, how its product(s)/service(s) works and who ultimately pays for its product/service(s).

In addition, we analyze whether the company generates positive cash flows.

Our analysis provides details regarding the business model, current share price, and what the management team has yet to accomplish.

Amaero (AMRO)

Nasdaq · First U.S. trade: October 15, 2026
Amaero: business, production and IPO snapshot.
Amaero: business, production and IPO snapshot.

Amaero began in 2013 when it spun out of Monash University, where it was based in Melbourne. It went public in Australia in 2019. In 2023, Amaero shut down all operations in Australia and is rebuilding in Tennessee on a single product line: creating metal powders for U.S. defense companies that want to buy from a U.S.-based source.

The NASDAQ stock listing generated $20 million, significantly less than the original goal of over $50 million. That money will be used to purchase additional equipment.

How Amaero turns metal bars into spherical powder.
How Amaero turns metal bars into spherical powder.

Metal 3D printing requires powdered made from nearly perfect spherical particles without contamination.
Amaero produces the powder using towers called atomizers. Currently three are running, and another one will be operating by June 2027.

Who buys it

The company supplies shops that produce printed parts for hypersonic weapon systems, satellite rocket engine components, missile components, commercial aircraft and medical implant components. Amaero claims to be the sole U.S. facility capable of producing both titanium and refractory alloy powders (the materials that can withstand extremely high temperatures), as well as pressing powder into completed, finished parts on its small secondary production line that has seen over 100% growth during Q1.

Amaero: revenue, production costs, orders and cash.
Amaero: revenue, production costs, orders and cash.

Our read

Demand appears strong. Since this time last year, the Order Book has nearly tripled, and Amaero currently has an exclusive Department of War Contract for refractory powders.
It’s at the factory that all of the cash is lost, during the previous quarter it took them $2.07 in expenses to make every $1 they made in Sales.
With Cash on hand from the IPO covering approximately 9 months of operations, we can reasonably anticipate another capital raise unless there are significant changes.

TC2000 charting and scanning software.
GB Capital’s assessment of Amaero’s technology, profitability, growth and valuation.
GB Capital’s assessment of Amaero’s technology, profitability, growth and valuation.

vVARDIS (VVVV)

NYSE · First trade: November 13, 2026
vVARDIS: Curodont, the founders and IPO snapshot.
vVARDIS: Curodont, the founders and IPO snapshot.

Haley and Goly Abivardi developed Swiss Smile, a dental clinic chain that opened in a Zurich train station mall in 2002.

The pair sold Swiss Smile, then they then developed vVARDIS in 2019, which acquired Credentis (the developer of a peptide for which there is over 25 years of R&D) one year later.

How Curodont works and how vVARDIS distributes it through Henry Schein.
How Curodont works and how vVARDIS distributes it through Henry Schein.

Dentists normally watch an early cavity until it is big enough to drill and fill. Curodont treats it at that early stage, in five minutes or less, with no drill and no needle.

Where it stands

Dentist’s generally will wait for an early cavity to grow before they can drill and fill it. Curodont treats this early stage of cavities in five minutes or less without drilling or using a needle.

Curodont first became available to U.S. dentists in January 2024 as an over-the-counter (OTC) anticavity product. More than three-and-one-half-million teeth have been treated by mid-2026 and over fifty U.S. dental school now incorporate teaching on how to treat cavities using Curodont. A fluoride-free version is marketed in Europe as a medical device.

TradeDeck market research software.

Built for swing traders and growth investors who hate being late to the move.

vVARDIS: sales, unit margin, debt and accumulated losses.
vVARDIS: sales, unit margin, debt and accumulated losses.

Our read

The product is selling. In the first half year, revenue has increased by a factor of three, while manufacturing cost per item decreased by 60%. However, we are concerned about two other items as much or even more than the loss.

For example, all U.S. orders go through Henry Schein and because the initial public offering was over-subscribed (buyers had pushed the stock down to $3 below its price at the time of the IPO), there may be some concerns regarding both the frequency with which practices reorder, and the terms of the distribution agreement with Schein.

GB Capital’s assessment of vVARDIS’s technology, profitability, growth and valuation.
GB Capital’s assessment of vVARDIS’s technology, profitability, growth and valuation.

Windward Bio (WWB)

Nasdaq · First trade: November 13, 2026
Windward Bio: investigational twice-yearly dosing and IPO snapshot.
Windward Bio: investigational twice-yearly dosing and IPO snapshot.

Windward was formed in 2024 by Luca Santarelli, an ex-Roche executive, when he sold two of his prior biotech companies (Therachon to Pfizer in 2019; Vectiv Bio to Ironwood for $1.2 billion in 2023).

It does not discover its drugs. It licenses antibodies from Chinese biotechs and runs the global trials.

WIN378: TSLP target, early clinical data and development stages.
WIN378: TSLP target, early clinical data and development stages.

Asthma can cause a person’s airways to become swollen and constrict when they encounter something. This reaction occurs because of a protein called TSLP (thymic stromal lymphopoietin) which can trigger inflammation in the airway.

Tezspire (tezepelumab) has been FDA-approved as an anti-inflammatory for severe asthma by blocking TSLP. Windward Bio’s investigational antibody also targets TSLP but is designed to be long-lasting in the body compared to Tezspire. The company has licensed antibodies from Kelun Biotech and Harbour BioMed. For these licenses, Windward will owe the two companies up to $970M depending on the success of their trials and sales.

Windward Bio: research spending, cash, funding and clinical milestones.
Windward Bio: research spending, cash, funding and clinical milestones.

Our read

Since there are no sales for us to review, we will be betting on the outcome of one clinical trial and one commercialization effort. The Phase 2 results are encouraging. Phase 3 still needs to confirm its efficacy and safety. So, at least part of what they are pitching is just about making things easier: giving people two shots per year instead of multiple every day or week.

The initial data set was made up of 147 patients, and the data seems solid. Initial data sets typically fade as time goes on and many times that is factored into the stock price after the initial price increase (or drop) on the first days of trading.

GB Capital’s assessment of Windward Bio’s technology, clinical risk and valuation.
GB Capital’s assessment of Windward Bio’s technology, clinical risk and valuation.

Thanks for reading Market Moves by GBC!

Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Always conduct your research and consult with a licensed financial advisor before making investment decisions.

Sources

  • Amaero Q3 2026 results (SEC)
  • Amaero Form 10-Q (SEC)
  • Amaero Form S-1/A (SEC)
  • Metal AM on the Amaero IPO filing
  • Metal AM on the Amaero IPO pricing
  • vVARDIS Form F-1/A (SEC)
  • Bloomberg via Swissinfo on the vVARDIS filing
  • Bloomberg via Swissinfo on the Apollo investment
  • IPOScoop on the vVARDIS pricing
  • Renaissance Capital weekly IPO recap
  • Renaissance Capital on the Windward Bio pricing
  • The Pharma Letter profile of Windward Bio
  • Fierce Biotech on the Windward IPO
  • StockAnalysis 2026 IPO list
Newsletter

This piece was free. The next one lands on Sunday.

Every Sunday, we analyze up to ten stocks and publish our market view. A subscription includes the full research, price levels and our live positions in the chat. The free section arrives by email.

Related research
2026 investment themes: space, AI and infrastructure | X-Ray 29Equity X-Ray · 31.12.2025Baidu (BIDU), tariffs and trade-war risk | Radar 70Wall Street Radar · 18.01.2026Galaxy Digital (GLXY): crypto and AI data centersEquity X-Ray · 10.06.2025Hut 8 (HUT), AI data centers and swing-trade stops | Radar 90Wall Street Radar · 21.06.2026Cerebras AI Chips: OpenAI Deal & Wafer-ScaleEquity X-Ray · 09.09.2026 Full archive →
FREE · EVERY SUNDAY

Get the next Radar
before Monday’s open.

The first name, the reasoning, and our public research.

FREE · EVERY SUNDAYGet the watchlist